Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pre-exposure Prophylaxis for Prevention of HIV Infection Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing a Patient Navigation Intervention for PrEP Continuum of Care Among Young Latino MSM (PrEParate)

NCT04048382
View directory record Official record
Conditions
HIV/AIDS
Interventions
Patient Navigation, Usual Care
Behavioral · Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 29 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

NCT03387462
View directory record Official record
Conditions
Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis, HIV Prevention
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app
Drug · Other
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Jul 22, 2026, 3:58 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

NCT07210125
View directory record Official record
Conditions
HIV
Interventions
Lenacapavir long-acting, Standard of Care (SOC)
Drug · Other
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men

NCT03771638
View directory record Official record
Conditions
Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis, HIV Prevention
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app
Drug · Other
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 22, 2026, 3:58 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Case Management Dyad

NCT06162897
View directory record Official record
Conditions
HIV, Pre-exposure Prophylaxis, Case Management
Interventions
Dyadic Case Management
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 3:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of the Pre-exposure Prophylaxis (PrEP) Cascade for Women.

NCT03705663
View directory record Official record
Conditions
Pre-Exposure Prophylaxis
Interventions
PrEP initiation
Behavioral
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

NCT01505114
View directory record Official record
Conditions
HIV Infection
Interventions
Maraviroc, Emtricitabine, Tenofovir disoproxil fumarate, Maraviroc placebo, Emtricitabine placebo, Tenofovir disoproxil fumarate placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

NCT04692077
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, CAB LA, Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 17 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Jul 22, 2026, 3:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Longer-Acting PrEP in Transgender and Gender Diverse Texans

NCT05044286
View directory record Official record
Conditions
HIV-1-infection
Interventions
no intervention
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers

NCT03202511
View directory record Official record
Conditions
Pre-Exposure Prophylaxis
Interventions
Probenecid Oral Tablet, Tenofovir disoproxil fumarate/Emtricitabine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 3 Interventional

Next Generation Ingestible Sensors for Medication Adherence Measurement

NCT05592613
View directory record Official record
Conditions
HIV Infection, Adherence, Medication, Adherence, Treatment, Pre-Exposure Prophylaxis, Antiretroviral Therapy
Interventions
Next-generation Reader and ID-Cap System, Truvada for pre-exposure prophylaxis (PrEP), Biktarvy for antiretroviral therapy (ART)
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Jul 22, 2026, 3:58 PM EDT
Not listed Not applicable Interventional

Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)

NCT03693040
View directory record Official record
Conditions
HIV Prevention
Interventions
Digital Health Feedback System
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Life Steps for PrEP for Youth

NCT03805451
View directory record Official record
Conditions
HIV, Pre-exposure Prophylaxis, Medication Adherence
Interventions
Life Steps for PrEP for Youth
Behavioral
Lead sponsor
Fenway Community Health
Other
Eligibility
16 Years to 24 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 22, 2026, 3:58 PM EDT
Recruiting Not applicable Interventional

Pre-exposure Prophylaxis (PrEP) for Health

NCT04430257
View directory record Official record
Conditions
Substance Dependence, HIV (Human Immunodeficiency Virus)
Interventions
HIV and PrEP education, Motivational interviewing, Problem-solving and planning, Patient navigation, PrEP information, Referrals
Other · Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Cambridge, Massachusetts • Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jul 22, 2026, 3:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinician Attitudes and Behaviors Regarding Use of Pre-Exposure Prophylaxis (PrEP) for Primary HIV Prevention

NCT01751659
View directory record Official record
Conditions
Clinician Attitudes About PrEP
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jul 22, 2026, 3:58 PM EDT
Recruiting Not applicable Interventional

Pre-exposure Prophylaxis (PrEP) Adherence Intervention for Women with Substance Use Disorders

NCT06158607
View directory record Official record
Conditions
Substance Use
Interventions
Addiction Clinic-Based PrEP Adherence Intervention for Women with Substance Use Disorders, Standard of care treatment
Behavioral · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Evaluation of a PrEP Decision Aid for Women Seeking Domestic Violence Services in Baltimore

NCT05614492
View directory record Official record
Conditions
HIV, Violence, Gender-Based, Pre-Exposure Prophylaxis
Interventions
Individual PrEP Decision Aid, CDC PrEP Video, Shared PrEP Decision Aid
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy

NCT04050371
View directory record Official record
Conditions
HIV Prevention, Transgender Health
Interventions
200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women

NCT03270969
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir Disoproxil Fumarate/Emtricitabine
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 22, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals

NCT03086200
View directory record Official record
Conditions
Patient Adherence, HIV Seronegativity
Interventions
brief Motivational Interviewing
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Jul 22, 2026, 3:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender Women

NCT07146139
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis, HIV Prevention and Care, Mobile Health Technology (mHealth), Adherence, Doxycycline STI PEP
Interventions
MyPrEP Plus Package, Standard of Care (SOC)
Device · Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jul 22, 2026, 3:58 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Client-Centered Care Coordination for Black Men Who Have Sex With Men

NCT06056544
View directory record Official record
Conditions
HIV Prevention, HIV Pre-exposure Prophylaxis
Interventions
Client Centered Care Coordination
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 22, 2026, 3:58 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

NCT04925752
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
3,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 22, 2026, 3:58 PM EDT